Importance clinique ... Un prédicteur des effets secondaires cholinergiques des inhibiteurs de l'acétylcholinestérase

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar du membre

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 4738
Enregistré le : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 8.1 Firefox
Genre :
Zodiaque : Lion
Âge : 61
Contact :
France

Importance clinique ... Un prédicteur des effets secondaires cholinergiques des inhibiteurs de l'acétylcholinestérase

Message par Pboulanger » 11 nov. 2016 15:46

:hi:

Lu sur http://synapse.koreamed.org/DOIx.php?id ... 6.12.4.482

Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Image
Clinical Significance of Repetitive Compound Muscle Action Potentials in Patients with Myasthenia Gravis::A Predictor for Cholinergic Side Effects of Acetylcholinesterase Inhibitors
Hyo Eun Lee, Yool-hee Kim, Seung Min Kim, Ha Young Shin



Background and Purpose

Acetylcholinesterase inhibitors (AChEIs) are widely used to treat myasthenia gravis (MG). Although AChEIs are usually tolerated well, some MG patients suffer from side effects. Furthermore, a small proportion of MG patients show cholinergic hypersensitivity and cannot tolerate AChEIs. Because repetitive compound muscle action potentials (R-CMAPs) are an electrophysiologic feature of cholinergic neuromuscular hyperactivity, we investigated the clinical characteristics of MG patients with R-CMAPs to identify their clinical usefulness in therapeutic decision-making.


Methods

We retrospectively reviewed the clinical records and electrodiagnostic findings of MG patients who underwent electrodiagnostic studies and diagnostic neostigmine testing (NT).


Results


Among 71 MG patients, 9 could not tolerate oral pyridostigmine bromide (PB) and 17 experienced side effects of PB. R-CMAPs developed in 24 patients after NT. The highest daily dose of PB was lower in the patients with R-CMAPs (240 mg/day vs. 480 mg/day, p<0.001). The frequencies of PB intolerance and side effects were higher in the patients with R-CMAPs than in those without R-CMAPs [37.5% vs. 0% (p<0.001) and 45.8% vs. 12.8% (p=0.002), respectively]. The MG Foundation of America postintervention status did not differ significantly between MG patients with and without R-CMAPs, and the response to immunotherapy was also good in both groups.


Conclusions

Side effects of and intolerance to AChEIs are more common in MG patients with R-CMAPs than in those without R-CMAPs. AChEIs should be used carefully in MG patients with R-CMAPs. The presence of R-CMAPs after NT may be a good indicator of the risks of PB side effects and intolerance.

Amicalement,
Image

Répondre

Retourner vers « Informations »